文献速递主动脉疾病

复杂血管腔内主动脉修复术后需输血出血或贫血的预测因素及其对健康保险理赔结局的影响

Predictors of bleeding or anemia requiring transfusion in complex endovascular aortic repair and its impact on outcomes in health insurance claims.
PubMed 文献 · J Vasc Surg · 2019-05-27

该研究基于德国DAK-Gesundheit健康保险理赔数据,分析2008至2017年间959例择期开窗或分支血管腔内动脉瘤修复术(FB-EVAR)患者,发现24.8%发生需输血的出血或贫血(BAT)。凝血病、女性和多重合并症是BAT的独立预测因素,BAT与更高的院内、30天和90天死亡率及主要并发症率相关,并关联更差的短期和长期生存。

要点

  • 凝血病、女性和多重合并症是FB-EVAR术后BAT的独立预测因素。
  • BAT组院内死亡率11.3% vs 2.6%,30天12.2% vs 3.1%,90天18.5% vs 4.4%。
  • BAT与更差短期生存(OR 3.19)和长期生存(HR 1.62)独立相关。

核心结论

  • 凝血病患者、多重合并症患者和女性在FB-EVAR后发生BAT的风险更高。
  • BAT的发生与更高的主要并发症率和更差的短期及长期生存强烈相关。

研究设计与样本

  • 基于德国第三大保险机构DAK-Gesundheit的健康保险理赔数据,纳入2008至2017年间择期FB-EVAR患者959例。

主要发现

  • BAT组患者年龄更大(74.4 vs 73.0岁;P = .015)。
  • BAT组充血性心力衰竭(18.5% vs 9.4%)、心律失常(26.9% vs 14.7%)和凝血病(31.9% vs 6.2%)更常见(均P < .001)。
  • 凝血病(OR 3.65;95%CI 2.29-5.84)、女性(OR 2.67;95%CI 1.78-4.00)和多重合并症(OR 1.10;95%CI 1.07-1.14)是BAT的独立预测因素(均P < .001)。
  • BAT组院内死亡率(11.3% vs 2.6%)、30天死亡率(12.2% vs 3.1%)和90天死亡率(18.5% vs 4.4%)更高(均P < .001)。
  • BAT组心肌梗死(23.9% vs 2.8%)和截瘫(9.7% vs 0.7%)更常见(均P < .001)。

临床怎么用

  • 对凝血病、多重合并症和女性FB-EVAR患者应加强围术期出血风险评估与监测。
  • 需进一步研究患者血液管理在FB-EVAR中的价值以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to determine predictors and outcomes associated with bleeding or anemia requiring transfusion (BAT) after fenestrated or branched endovascular aneurysm repair (FB-EVAR). METHODS: Health insurance claims data of Germany's third largest insurance provider, DAK-Gesundheit, were used to investigate BAT in elective FB-EVAR performed between 2008 and 2017. International Classification of Diseases and German Operations and Procedure Key codes were used. RESULTS: A total of 959 patients (24.8% with BAT) matching the inclusion criteria were identified during the study period. Compared with patients without BAT, patients with BAT were older (74.4 vs 73.0 years; P = .015) and suffered more frequently from congestive heart failure (18.5% vs 9.4%), cardiac arrhythmias (26.9% vs 14.7%), and hereditary or acquired coagulopathy (31.9% vs 6.2%; all P < .001). Coagulopathy (odds ratio [OR], 3.65; 95% confidence interval [CI], 2.29-5.84), female sex (OR, 2.67; 95% CI, 1.78-4.00), and multiple comorbidities (OR, 1.10; 95% CI, 1.07-1.14) were independent predictors of BAT (all P < .001). BAT was associated with higher in-hospital (11.3% vs 2.6%), 30-day (12.2% vs 3.1%), and 90-day (18.5% vs 4.4%) mortality (all P < .001). Furthermore, myocardial infarction (23.9% vs 2.8%) and paraplegia (9.7% vs 0.7%) were more frequent in the BAT group (all P < .001). In multivariable analyses, BAT was associated with worse short-term (OR, 3.19; 95% CI, 1.63-6.33; P = .001) and long-term survival (hazard ratio, 1.62; 95% CI, 1.24-2.11; P < .001). CONCLUSIONS: Patients with hereditary or acquired coagulopathy, patients with multiple comorbidities, and women are at higher risk for development of BAT after FB-EVAR. The occurrence of this event was strongly associated with higher major complication rates and worse short-term and long-term survival. This emphasizes a need to further illuminate the value of patient blood management in FB-EVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Behrendt CA, Debus ES, Schwaneberg T, et al. Predictors of bleeding or anemia requiring transfusion in complex endovascular aortic repair and its impact on outcomes in health insurance claims. J Vasc Surg. 2019. PMID: 31147140. doi:10.1016/j.jvs.2019.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。